Rare lymphomas

After a decade of tremendous progress in the diagnostic and therapeutic approaches to malignant lymphoma, optimal treatment strategies are now based not only on accurate diagnosis but also on thorough evaluation of clinical and molecular risk factors. Even more importantly, molecular targeted approa...

Full description

Saved in:
Bibliographic Details
Other Authors: Dreyling, Martin (Editor), Williams, Michael E. 1951- Michael Eugene (Editor)
Format: Book
Published: Berlin Springer 2014
Series:Hematologic malignancies
Subjects:
Online Access:Click Here to View Status and Holdings.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000nam a2200000#i 4501
001 wils-523632
005 2023910142217
020 # # |a 9783642395895  |q hardback 
020 # # |a 3642395899  |q hardback 
040 # # |a StDuBDS  |d UiTM  |e rda 
041 0 # |a English 
060 0 0 |a WH 525 
090 0 0 |a WH525  |b R2218 2014 
245 0 0 |a Rare lymphomas  |c edited by Martin Dreyling, Michael E. Williams 
264 # 1 |a Berlin  |b Springer  |c 2014 
264 # 4 |c ©2014 
300 # # |a 1 volume, x, 364 pages  |b illustrations  |c 26 cm 
336 # # |a text  |b txt  |2 rdacontent 
337 # # |a unmediated  |b n  |2 rdamedia 
338 # # |a volume  |b nc  |2 rdacarrier 
490 1 # |a Hematologic malignancies 
504 # # |a Includes bibliographical references 
520 # # |a After a decade of tremendous progress in the diagnostic and therapeutic approaches to malignant lymphoma, optimal treatment strategies are now based not only on accurate diagnosis but also on thorough evaluation of clinical and molecular risk factors. Even more importantly, molecular targeted approaches have been shown to be effective in the treatment of distinct lymphoma subtypes. Against this background, clinical management of especially the rare lymphomas remains a challenge for the general oncologist. This book provides a comprehensive overview of current treatment strategies in these rare lymphoma subtypes. Experts in the field from around the world describe histomorphology in a clinically relevant manner, consider the role of risk factors in detail, and discuss the spectrum of therapeutic approaches. Special emphasis is placed on the translation of molecular science into clinical care, and a disease-specific algorithm is proposed for each entity 
650 1 2 |a Lymphomas 
650 2 2 |a Rare diseases 
700 1 # |a Dreyling, Martin  |e editor 
700 1 # |a Williams, Michael E.  |d 1951-  |e editor  |q Michael Eugene 
856 4 0 |z Click Here to View Status and Holdings.  |u https://opac.uitm.edu.my/opac/detailsPage/detailsHome.jsp?tid=523632 
998 # # |a 00264#1a006.2.2||00264#1b006.2.2||00300##a006.2.2||00300##b006.2.2||00300##c006.2.2||00520##a006.2.2||00520##b006.2.2||